Sucampo Pharmaceuticals, Inc. Announces Exclusive Licensing Agreement With Fujisawa for Ophthalmic Use of Tacrolimus

"This license agreement is a major milestone for Sucampo Pharmaceuticals," said Chair and CEO Ryuji Ueno, M.D., Ph.D., PhD. "We have an enormous amount of ophthalmic research and development expertise. In licensing their flagship compound to us for ophthalmic use, Fujisawa has validat...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire p. 1
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 19.02.2002
Subjects
Agreements
Chief executive officers
Glaucoma
Industry profiles
Licenses
Licensing
Pharmaceutical industry
R&D
Research & development
United States > US
Bethesda Maryland
Maryland, Japan
Online AccessGet full text

Cover

More Information
Summary:"This license agreement is a major milestone for Sucampo Pharmaceuticals," said Chair and CEO Ryuji Ueno, M.D., Ph.D., PhD. "We have an enormous amount of ophthalmic research and development expertise. In licensing their flagship compound to us for ophthalmic use, Fujisawa has validated this. This is a truly great event, which we are very pleased to share with everyone." Sucampo Pharmaceuticals, Inc. is the U.S. operating branch of the Sucampo Group. It oversees manufacturing, distribution and marketing of pharmaceutical products and leads research and development programs for the Group pipeline compounds in the Americas. These compounds are based on [Ueno]'s research that led to the discovery of a novel class of bioactive lipids. Ueno is an internationally recognized expert in the pharmacology, physiology and biochemistry of naturally occurring (endogenous) fatty acids and their related compounds. These bioactive lipids are the subject of more than 650 patents worldwide and are at the center of the company's research and development.